Pharma Journalist -

Kynexis, a clinical-stage biotechnology company developing treatments for cognitive problems linked to brain diseases, has raised €40 million in a Series A financing extension. The…
Read More...

Regeneron Pharmaceuticals has received U.S. Food and Drug Administration approval for Pasatru (garetosmab-grts), a new treatment for adults living with fibrodysplasia ossificans…
Read More...

Consano Bio has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for C-1101, an investigational treatment being developed for chronic, painful…
Read More...

BioMarin Pharmaceutical has agreed to acquire Alesta Therapeutics in a deal aimed at adding a potential new treatment for hypophosphatasia (HPP), a rare genetic bone disease, to its…
Read More...

Clinical translation insights to accelerate the development of differentiated autoimmune T-cell engager therapies. Following rapid progress in the autoimmune T-cell engager field,…
Read More...

Fulcrum Therapeutics and Slate Medicines have agreed to combine in an all-stock merger that will create a company focused on developing new treatments for migraine and other headache…
Read More...

LEO Pharma has agreed to acquire worldwide rights to dersimelagon from Tanabe Pharma in a deal that could reach up to $435 million in upfront and near-term milestone payments.…
Read More...

Sandoz and Shanghai Henlius Biotech have entered into a major collaboration to develop, manufacture and commercialize biosimilar medicines, with the aim of expanding access to…
Read More...

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Phanes Therapeutics’ spevatamig for the treatment of patients with advanced and metastatic biliary…
Read More...

The European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for Pfizer and Valneva’s investigational Lyme disease vaccine, allowing the regulatory…
Read More...